Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Nov 29:14:1322180.
doi: 10.3389/fmicb.2023.1322180. eCollection 2023.

Aztreonam-avibactam synergy, a validation and comparison of diagnostic tools

Affiliations

Aztreonam-avibactam synergy, a validation and comparison of diagnostic tools

Gil Verschelden et al. Front Microbiol. .

Abstract

Introduction: Antimicrobial resistance is a growing problem that necessitates the development of new therapeutic options. Cefiderocol and aztreonam (AT) are often the last active β-lactams for treating metallo-β-lactamases (MBL)-producing Gram-negative bacilli. In these difficult-to-treat bacterial strains, AT resistance is frequently attributed to the co-occurrence of other resistance mechanisms. In the case of β-lactamases they can often be inhibited by avibactam. In the present study, we evaluated the use of the double-disc synergy test (DDST) as a screening tool for the detection of synergy between AT-avibactam (ATA). We validated both the Gradient Diffusion Strips (GDSs) superposition method and the commercially available Liofilchem's ATA GDS.

Materials and methods: We tested AT susceptibility in combination with ceftazidime-avibactam for 65 strains, including 18 Serine-β-Lactamase (SBL)- and 24 MBL-producing Enterobacterales, 12 MBL-producing P. aeruginosa, and 11 S. maltophilia isolates. Interpretation was done with EUCAST breakpoints (version 13.0), AT breakpoints being used for ATA. The accuracy and validity of the GDSs superposition method and ATA GDS were evaluated using an AT GDS applied on Mueller Hinton Agar plates supplemented with avibactam (MH-AV). A DDST was performed to screen for synergy between antibiotic combinations.

Results: Using MH-AV, all SBL- and MBL-positive Enterobacterales were susceptible or susceptible at increased exposure to the combination AT-avibactam. In contrast, only 2 out of the 12 (17%) P. aeruginosa strains and 9/11 (82%) of the S. maltophilia strains were susceptible- or susceptible at increased exposure for the combination of AT-avibactam. The DDST detected all synergies, demonstrating a 100% sensitivity and 100% negative predictive value for all bacterial strains.

Conclusion: The DDST is a sensitive tool for screening for antibiotic synergy. Unlike S. maltophilia and SBL- and MBL-positive Enterobacterales, most MBL-positive P. aeruginosa strains remain resistant to AT-avibactam. ATA GDS should be preferred for MIC determination of the AT-avibactam combination, while the GDSs superposition method can be used as an alternative to the commercial test.

Keywords: Enterobacterales; P. aeruginosa; S. maltophilia; antibiotic synergy; antimicrobial resistance; avibactam; aztreonam; ceftazidime/avibactam.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
(A) Aztreonam (AT) and Ceftazidime-avibactam (CZA) double-disc synergy test. (B) Left: controle AT Gradient diffusion strip (GDS), Right: AT and CZA GDSs superposition methode.
Figure 2
Figure 2
(A) Left: controle Aztreonam (AT) Gradient diffusion strip (GDS), Middle: AT and cefazidime-avibactam (CZA) GDSs superposition methode, Right: AT and amoxicillin clavulanic acid (AMC) GDSs superposition methode. (B) AT-CZA and AT-AMC double-disc synergy test.

References

    1. Akbar W. (2019). Ten threats to global health in 2019. Available at: https://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-... (Accessed June 24, 2023).
    1. Antimicrobial resistance surveillance in Europe 2023–2021 data (2023). Stockholm: European Centre for Disease Prevention and Control and World Health Organization. Cataloguing-in-Publication (CIP) data. Available at: http://apps.who.int/iris. (Accessed June 24, 2023).
    1. Biagi M., Lamm D., Meyer K., Vialichka A., Jurkovic M., Patel S., et al. (2020). Activity of Aztreonam in combination with avibactam, Clavulanate, Relebactam, and Vaborbactam against multidrug-resistant Stenotrophomonas maltophilia. Antimicrob. Agents Chemother. 64, e00297–e00220. doi: 10.1128/AAC.00297-20, PMID: - DOI - PMC - PubMed
    1. Brolund A., Lagerqvist N., Byfors S., Struelens M. J., Monnet D. L., Albiger B., et al. (2019). Worsening epidemiological situation of carbapenemase-producing Enterobacteriaceae in Europe, assessment by national experts from 37 countries, July 2018. Euro Surveill. 24:1900123. doi: 10.2807/1560-7917.ES.2019.24.9.1900123, PMID: - DOI - PMC - PubMed
    1. Bush K. (2018). Past and present perspectives on β-lactamases. Antimicrob. Agents Chemother. 62, e01076–e01018. doi: 10.1128/AAC.01076-18, PMID: - DOI - PMC - PubMed

LinkOut - more resources